Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory ...

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

SANTA ANA, Calif. - NKGen Biotech, Inc. (NASDAQ: NKGN), a clinical-stage biotechnology company with a current market capitalization of $17 million, has received Fast Track designation from the U.S.

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5BOCA RATON, ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

Brain metastases are one of the most severe complications of melanoma, the most aggressive type of skin cancer. Researchers at the Institute for Neurosciences (IN), a joint center of the Spanish ...

Solid tumors that originate in the deep internal organs, such as the pancreas, liver, and ovary, have poor prognoses due to the difficulties of diagnosing ...

Prof. MENG Guangxun's team from the Shanghai Institute of Immunity and Infection of the Chinese Academy of Sciences, and collaborators, have revealed a novel mechanism whereby a short form of IL-18, ...